Effectiveness of topical corticosteroids in addition to antiviral therapy in the management of recurrent herpes labialis: a systematic review and meta-analysis
Autor: | Nasira, Arain, Sharath C V, Paravastu, Mubashir A, Arain |
---|---|
Rok vydání: | 2014 |
Předmět: |
Recurrent herpes infection
Cold sores Famciclovir Acyclovir Administration Oral Valine Administration Cutaneous Antiviral Agents Meta-analysis Treatment Outcome Adrenal Cortex Hormones Recurrence Valacyclovir Herpes labialis Humans Drug Therapy Combination Female Corticosteroids and Herpes infection 2-Aminopurine Research Article |
Zdroj: | BMC Infectious Diseases |
ISSN: | 1471-2334 |
Popis: | Background Recurrent herpes labialis (RHL) is one of the most common viral infections worldwide. The available treatments have limited efficacy in preventing the recurrence of ulcerative lesions and reducing the duration of illness. The objective of this review was to identify the effectiveness of topical corticosteroids in addition to antiviral therapy in the treatment of RHL infection. Methods A systematic review of randomized clinical trials comparing the efficacy of combined therapy (topical corticosteroids with antiviral) with placebo or antiviral alone in the management of RHL was conducted. MEDLINE, EMBASE, CINAHL, Web of Science, the Cochrane library, and Google Scholar databases were searched. We used RevMan software to conduct the meta-analysis. A fixed-effects model was used for mild to moderate heterogeneity, whereas a random-effects model was used for significant heterogeneity. Heterogeneity among trials was established using I2 and chi-square test for heterogeneity. Results Four studies that fulfilled the selection criteria were included in this review. The total number of participants across included studies was 1,891 (range, 29 to 1,443). The antiviral drugs used were acyclovir, famciclovir, and valacyclovir. Corticosteroids used were 1% hydrocortisone and 0.05% fluocinonide. Pooled results showed that patients receiving combined therapy had a significantly lower recurrence rate of ulcerative lesions compared to those in both the placebo group (OR, 0.50; 95% CI, 0.39-0.66; P |
Databáze: | OpenAIRE |
Externí odkaz: |